Sanofi India's (SANL) 2QCY12 operational performance was in line with Motilal Oswal's expectations. Key highlights:
- Net sales grew 23.5% YoY to Rs3.74b v/s their estimate of Rs3.7b. Motilal Oswal believes topline growth has been led by strong growth in domestic revenue on consolidation of Universal Medicare acquisition. Exports are also likely to have grown during the quarter.
- EBITDA grew 22% YoY to Rs522m v/s estimate of Rs537m. EBITDA margin contracted 10bp to 14% v/s our estimate of 14.5%.
- Adjusted PAT declined 18.5% YoY to Rs405m and was lower than Motilal Oswal's estimate of Rs442m due to higher amortization cost relating to the brands and technical knowhow acquired from Universal Medicare in 2011.
- SANL has, in the past, indicated that for the domestic business, the rural and OTC segments will be the key growth drivers, and that it is likely to incur extra expenditure to establish its presence in these segments. This is likely to pressurize short-term profitability.
Stock valuation and recommendation
Motilal Oswal believes SANL will be one of the key beneficiaries of the patent regime in the long-term. The parent has a strong R&D pipeline with a total of 61 products undergoing clinical trials, of which 18 are in Phase-III or pending approvals. Some of these are likely to be launched in India. However, SANL's profitability has declined significantly in the last five years, with EBITDA margin declining from 25% in CY06 to 14.3% in CY11, mainly impacted by discontinuation of Rabipur sales in the domestic market, lower export growth and higher staff & promotional expenses. RoE has declined from 28.6% to 17.3% during the period. The stock trades at 29.9x CY12E and 23.8x CY13E EPS. Motilal Oswal believes that the stock performance will remain muted in the short term until clarity emerges on future growth drivers. Maintain Neutral.
Click here to read the full report
Motilal Oswal was founded in 1987 as a small sub-broking unit, with just two people running the show. Today it has a 2000 member team with a networth of Rs7 bn and market capitalization as of March 31, 2008 at Rs19 bn.
For more information please write in to firstname.lastname@example.org
Disclaimer: The author has taken due care and caution to compile and analyse the data. The opinions expressed above are only the views of the author, and not a recommendation to buy or sell. Neither the author nor IndiaNotes.com accept any liability whatsoever arising from the use of any of the above contents.
- Sanofi India Q4CY14 Preview: Price cuts to impact revenue growth
- Sanofi India Q2FY15: Results below estimate
- Q2FY15 Preview: Buy Sanofi India at CMP of Rs3291
- Sanofi India: Q2CY14 net rises 12.30%, maintain buy
- Sanofi India: Accumulate between Rs2872 and Rs2457
Have a question?
Also On IndiaNotes.Com
- Buy NTPC above 157 with a stop loss below 130
- Short term advice: Buy this stock for target price 145